Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06735534 · ClinicalTrials.gov registry record · NA
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
A NA study of Persistent Atrial Fibrillation, sponsored by Boston Scientific Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 407
- Enrollment target
- 20
- Study locations
NCT06735534: Recruiting NA study of Persistent Atrial Fibrillation, sponsored by Boston Scientific Corporation.
NCT06735534 is a NA study of Persistent Atrial Fibrillation that is actively recruiting participants, run by Boston Scientific Corporation. The registered enrollment target is 407 participants, below the 1,233-participant average among 15 other Persistent Atrial Fibrillation trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06735534, a NA study of Persistent Atrial Fibrillation, is actively recruiting participants, sponsored by Boston Scientific Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 407 participants
- Enrollment target
- 20
- Study locations
Study Summary
The ReMATCH Study is a prospective, single arm, open label, multi-center, study utilizing the FARAPULSE PFA System, including the FARAWAVE and FARAPOINT PFA Catheters.
Primary Outcome
The primary safety endpoint (PSE) is the proportion of Treatment subjects with one or more device or procedure-related Composite Serious Adverse Events (CSAEs) following the Repeat Ablation Procedure.
Conditions Studied
Interventions
- DEVICE FARAPULSE™ Pulsed Field Ablation System
Study Locations (20)
California
- University of Southern California Hospital - Los Angeles
- Stanford University Medical Center - Stanford
Florida
- HCA Florida Mercy Hospital - Miami
- Naples Comprehensive Health - Naples
Georgia
- Emory University Hospital - Atlanta
- Memorial Health University Medical Center - Savannah
Massachusetts
- Massachusetts General Hospital - Boston
- Southcoast Physicians Group - Fall River
Ohio
- Bethesda North Hospital - Cincinnati
- Ohio State University Medical Center - Columbus
Alabama
- Mobile Infirmary Medical Center - Mobile
Arkansas
- Arrhythmia Research Group-Research Facility - Jonesboro
Colorado
- South Denver Cardiology Associates, PC - Littleton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2025-06-03 |
| Est. Completion | 2028-01 |
| Phase | NA |
What NCT06735534 shows while recruiting
NCT06735534 is an interventional study that assigns participants to a tested intervention. The registered 407 participants enrollment target is mid-sized for trials with a published cap, below the 1,233-participant average among 15 other Persistent Atrial Fibrillation trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Persistent Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which FARAPULSE™ Pulsed Field Ablation System is the first listed.
NCT06735534 names 20 study sites across 15 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06735534 about?
NCT06735534 is a clinical study titled "Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System". The ReMATCH Study is a prospective, single arm, open label, multi-center, study utilizing the FARAPULSE PFA System, including the FARAWAVE and FARAPOINT PFA Catheters.
What is the current status of trial NCT06735534?
This trial is currently recruiting. It is a NA study. The enrollment target is 407 participants. The study started on 2025-06-03. Estimated completion is 2028-01.
What conditions does trial NCT06735534 study?
This clinical trial studies the following conditions: Persistent Atrial Fibrillation.
What interventions are being tested in trial NCT06735534?
The interventions under investigation include: FARAPULSE™ Pulsed Field Ablation System (DEVICE).
Who is sponsoring clinical trial NCT06735534?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06735534 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Persistent Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06735534's enrollment target sits among peer trials
407 4th of 15 higher than 12 of 15 other Persistent Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Persistent Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Endocardial Mapping With the CoreMap EP Mapping System
RECRUITING · NA
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
ARIADNE Clinical Trial
RECRUITING · NA
-
Medtronic Terminate AF Study
RECRUITING · NA
-
Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
ACTIVE NOT RECRUITING · NA
-
AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07094516 · 407 participants · Phase 2
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
- NCT04835428 · 408 participants · NA
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
- NCT05836324 · 408 participants · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- NCT05863195 · 408 participants · Phase 3
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI